224 related articles for article (PubMed ID: 9724478)
1. Intravenous bisphosphonate prevents symptomatic osteoporotic vertebral collapse in patients after liver transplantation.
Reeves HL; Francis RM; Manas DM; Hudson M; Day CP
Liver Transpl Surg; 1998 Sep; 4(5):404-9. PubMed ID: 9724478
[TBL] [Abstract][Full Text] [Related]
2. Prevention of bone loss and fracture after lung transplantation: a pilot study.
Cahill BC; O'Rourke MK; Parker S; Stringham JC; Karwande SV; Knecht TP
Transplantation; 2001 Oct; 72(7):1251-5. PubMed ID: 11602851
[TBL] [Abstract][Full Text] [Related]
3. Better late than never? Experience with intravenous pamidronate treatment in patients with low bone mass or fractures following cardiac or liver transplantation.
Dodidou P; Bruckner T; Hosch S; Haass M; Klar E; Sauer P; Ziegler R; Leidig-Bruckner G
Osteoporos Int; 2003 Jan; 14(1):82-9. PubMed ID: 12577189
[TBL] [Abstract][Full Text] [Related]
4. Intravenous pamidronate compared with oral alendronate for the treatment of postmenopausal osteoporosis.
Heijckmann AC; Juttmann JR; Wolffenbuttel BH
Neth J Med; 2002 Sep; 60(8):315-9. PubMed ID: 12481878
[TBL] [Abstract][Full Text] [Related]
5. Intravenous pamidronate in juvenile osteoporosis.
Shaw NJ; Boivin CM; Crabtree NJ
Arch Dis Child; 2000 Aug; 83(2):143-5. PubMed ID: 10906023
[TBL] [Abstract][Full Text] [Related]
6. Incidence of vertebral fractures in the first three months after orthotopic liver transplantation.
Ninkovic M; Skingle SJ; Bearcroft PW; Bishop N; Alexander GJ; Compston JE
Eur J Gastroenterol Hepatol; 2000 Aug; 12(8):931-5. PubMed ID: 10958221
[TBL] [Abstract][Full Text] [Related]
7. Lack of effect of intravenous pamidronate on fracture incidence and bone mineral density after orthotopic liver transplantation.
Ninkovic M; Love S; Tom BD; Bearcroft PW; Alexander GJ; Compston JE
J Hepatol; 2002 Jul; 37(1):93-100. PubMed ID: 12076867
[TBL] [Abstract][Full Text] [Related]
8. High-dose bisphosphonate therapy in an urgent case of spontaneous multiple vertebral fractures in a 55 year old woman.
Muschitz C; Roschger P; Patsch J; Pollhammer I; Koller B; Klaushofer K; Resch H
Wien Med Wochenschr; 2007; 157(15-16):388-91. PubMed ID: 17922087
[TBL] [Abstract][Full Text] [Related]
9. Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.
Gallacher SJ; Fenner JA; Anderson K; Bryden FM; Banham SW; Logue FC; Cowan RA; Boyle IT
Thorax; 1992 Nov; 47(11):932-6. PubMed ID: 1465751
[TBL] [Abstract][Full Text] [Related]
10. Osteoporosis in lung transplantation candidates with end-stage pulmonary disease.
Shane E; Silverberg SJ; Donovan D; Papadopoulos A; Staron RB; Addesso V; Jorgesen B; McGregor C; Schulman L
Am J Med; 1996 Sep; 101(3):262-9. PubMed ID: 8873487
[TBL] [Abstract][Full Text] [Related]
11. Bone densitometry in pediatric patients treated with pamidronate.
Grissom LE; Kecskemethy HH; Bachrach SJ; McKay C; Harcke HT
Pediatr Radiol; 2005 May; 35(5):511-7. PubMed ID: 15655696
[TBL] [Abstract][Full Text] [Related]
12. Effects of 3 years of intravenous pamidronate treatment on bone markers and bone mineral density in a patient with osteoporosis-pseudoglioma syndrome (OPPG).
Bayram F; Tanriverdi F; Kurtoğlu S; Atabek ME; Kula M; Kaynar L; Keleştimur F
J Pediatr Endocrinol Metab; 2006 Mar; 19(3):275-9. PubMed ID: 16607930
[TBL] [Abstract][Full Text] [Related]
13. Changes in bone mineral density after kidney transplantation: 2-year assessment of a French cohort.
Segaud N; Legroux I; Hazzan M; Noel C; Cortet B
Osteoporos Int; 2018 May; 29(5):1165-1175. PubMed ID: 29500526
[TBL] [Abstract][Full Text] [Related]
14. Prevention of bone loss after heart transplantation with antiresorptive therapy: a pilot study.
Shane E; Rodino MA; McMahon DJ; Addesso V; Staron RB; Seibel MJ; Mancini D; Michler RE; Lo SH
J Heart Lung Transplant; 1998 Nov; 17(11):1089-96. PubMed ID: 9855448
[TBL] [Abstract][Full Text] [Related]
15. Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study.
Krieg MA; Seydoux C; Sandini L; Goy JJ; Berguer DG; Thiébaud D; Burckhardt P
Osteoporos Int; 2001; 12(2):112-6. PubMed ID: 11303710
[TBL] [Abstract][Full Text] [Related]
16. The effect of intravenous pamidronate versus oral alendronate on bone mineral density in patients with osteoporosis.
Vis M; Bultink IE; Dijkmans BA; Lems WF
Osteoporos Int; 2005 Nov; 16(11):1432-5. PubMed ID: 15883662
[TBL] [Abstract][Full Text] [Related]
17. The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy.
Sbrocchi AM; Rauch F; Jacob P; McCormick A; McMillan HJ; Matzinger MA; Ward LM
Osteoporos Int; 2012 Nov; 23(11):2703-11. PubMed ID: 22297733
[TBL] [Abstract][Full Text] [Related]
18. Risk of vertebral fractures in men: relationship to mineral density of the vertebral body.
Resch A; Schneider B; Bernecker P; Battmann A; Wergedal J; Willvonseder R; Resch H
AJR Am J Roentgenol; 1995 Jun; 164(6):1447-50. PubMed ID: 7754890
[TBL] [Abstract][Full Text] [Related]
19. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis.
Meunier PJ; Roux C; Seeman E; Ortolani S; Badurski JE; Spector TD; Cannata J; Balogh A; Lemmel EM; Pors-Nielsen S; Rizzoli R; Genant HK; Reginster JY
N Engl J Med; 2004 Jan; 350(5):459-68. PubMed ID: 14749454
[TBL] [Abstract][Full Text] [Related]
20. Intravenous Bisphosphonate Therapy of Young Children With Osteogenesis Imperfecta: Skeletal Findings During Follow Up Throughout the Growing Years.
Palomo T; Fassier F; Ouellet J; Sato A; Montpetit K; Glorieux FH; Rauch F
J Bone Miner Res; 2015 Dec; 30(12):2150-7. PubMed ID: 26059976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
